Aptevo Therapeutics Inc. and Alligator Bioscience have entered into an agreement to co-develop an immunotherapy bispecific antibody candidate, ALG.APV-527, based on Alligator’s first generation bispecific antibody, ATOR-1016.  The new candidate was developed using Aptevo’s bispecific technology platform and includes binding elements generated by Alligator’s ALLIGATOR-GOLDantibody library. The companies plan to initiate cell line development for the manufacture of clinical material soon. Worki...